Having found a high frequency of IDH1 and IDH2 mutations in subtypes of gliomas, we hypothesised role in long-term follow-up studies, finding that both IDH1 and IDH2 mutations are strong prognostic factors, supporting other data (15, 16). Here, IDH1 is linked to central nervous system cancer.